South America Human Papillomavirus Vaccine Market Analysis/Forecasts Report 2022-2028 Featuring GlaxoSmithKline, Inovio Pharmaceuticals, Merck & Co, R-Pharm, Sanofi, & Serum Institute of India - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Nov 21, 2022--

The "South America Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

The South America human papillomavirus (HPV) vaccine market is expected to grow from US$ 173.52 million in 2022 to US$ 239.53 million by 2028; it is estimated to grow at a CAGR of 5.5% from 2022 to 2028.

Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples.

This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV).

The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers - p16 and Ki-67 - in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers means the person taking the test is at a high risk of getting the disease. Such robust developments in HPV diagnostics tests are likely to reshape the market during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America human papillomavirus (HPV) vaccine market . The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

South America Human Papillomavirus (HPV) Vaccine Market Segmentation

• The quadrivalent HPV vaccine segment would dominate the market in 2022. In terms of dosage, the South America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment would dominate the market in 2022.
• The 9 to 14 years segment would dominate the market in 2022. In terms of application, the South America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment would dominate the market in 2022.
• The hospitals segment would dominate the market in 2022.
• Brazil would dominate the market in 2022.

Key Market Dynamics

Market Drivers

• Increase in Prevalence of HPV Associated Diseases
• Initiatives Taken by Health Organizations

Market Restraints

• High Cost of HPV Vaccines

Future Trends

• Advancements in HPV Diagnostics Tests

Company Profiles

• GlaxoSmithKline plc.
• Inovio Pharmaceuticals
• Merck & Co., Inc.
• R-Pharm
• Sanofi
• Serum Institute of India Pvt. Ltd

For more information about this report visit https://www.researchandmarkets.com/r/cu2hwl

View source version on businesswire.com:https://www.businesswire.com/news/home/20221121005456/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: SOUTH AMERICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.